Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Issue 1 (December 2018)
- Record Type:
- Journal Article
- Title:
- Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Issue 1 (December 2018)
- Main Title:
- Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis
- Authors:
- Kussmann, Manuel
Karer, Matthias
Obermueller, Markus
Schmidt, Katy
Barousch, Wolfgang
Moser, Doris
Nehr, Marion
Ramharter, Michael
Poeppl, Wolfgang
Makristathis, Athanasios
Winkler, Stefan
Thalhammer, Florian
Burgmann, Heinz
Lagler, Heimo - Abstract:
- Abstract In the present study, we demonstrated the emergence of dalbavancin non-susceptible and teicoplanin-resistantStaphylococcus aureus small colony variants which were selected in vivo through long-term treatment with dalbavancin. A 36-year-old man presented with a cardiac device-relatedS. aureus endocarditis and received long-term therapy with dalbavancin. Consecutively, two glycopeptide/lipoglycopeptide susceptible and two non-susceptibleS. aureus isolates were obtained from blood cultures and the explanted pacemaker wire. The isolates were characterized by: standard typing methods, antimicrobial susceptibility testing, auxotrophic profiling, proliferation assays, scanning and transmission electron microscopy, as well as whole genome sequencing. The isolated SCVs demonstrated a vancomycin-susceptible but dalbavancin non-susceptible and teicoplanin-resistant phenotype whereof the respective MICs of the last isolate were 16- and 84-fold higher than the susceptible strains. All four strains were indistinguishable or at least closely related by standard typing methods (spa, MLST, and PFGE), and whole genome sequencing revealed only eight sequence variants. A consecutive increase in cell wall thickness (up to 2.1-fold), an impaired cell separation with incomplete or multiple cross walls and significantly reduced growth rates were observed in the present study. Therefore, the mutations inpbp2 and the DHH domain of GdpP were identified as the most probable candidates due toAbstract In the present study, we demonstrated the emergence of dalbavancin non-susceptible and teicoplanin-resistantStaphylococcus aureus small colony variants which were selected in vivo through long-term treatment with dalbavancin. A 36-year-old man presented with a cardiac device-relatedS. aureus endocarditis and received long-term therapy with dalbavancin. Consecutively, two glycopeptide/lipoglycopeptide susceptible and two non-susceptibleS. aureus isolates were obtained from blood cultures and the explanted pacemaker wire. The isolates were characterized by: standard typing methods, antimicrobial susceptibility testing, auxotrophic profiling, proliferation assays, scanning and transmission electron microscopy, as well as whole genome sequencing. The isolated SCVs demonstrated a vancomycin-susceptible but dalbavancin non-susceptible and teicoplanin-resistant phenotype whereof the respective MICs of the last isolate were 16- and 84-fold higher than the susceptible strains. All four strains were indistinguishable or at least closely related by standard typing methods (spa, MLST, and PFGE), and whole genome sequencing revealed only eight sequence variants. A consecutive increase in cell wall thickness (up to 2.1-fold), an impaired cell separation with incomplete or multiple cross walls and significantly reduced growth rates were observed in the present study. Therefore, the mutations inpbp2 and the DHH domain of GdpP were identified as the most probable candidates due to their implication in the biosynthesis and metabolism of the staphylococcal cell wall. For the first time, we demonstrated in vivo induced dalbavancin non-susceptible/teicoplanin resistant, but vancomycin and daptomycin susceptibleS. aureus SCVs without lipopeptide or glycopeptide pretreatment, thus, indicating the emergence of a novel lipoglycopeptide resistance mechanism. … (more)
- Is Part Of:
- Emerging microbes & infections. Volume 7:Issue 1(2018)
- Journal:
- Emerging microbes & infections
- Issue:
- Volume 7:Issue 1(2018)
- Issue Display:
- Volume 7, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 7
- Issue:
- 1
- Issue Sort Value:
- 2018-0007-0001-0000
- Page Start:
- 1
- Page End:
- 10
- Publication Date:
- 2018-12
- Subjects:
- Medical microbiology -- Periodicals
Communicable diseases -- Periodicals
Infection -- Periodicals
616.9041 - Journal URLs:
- http://www.nature.com/ ↗
https://www.nature.com/emi/ ↗ - DOI:
- 10.1038/s41426-018-0205-z ↗
- Languages:
- English
- ISSNs:
- 2222-1751
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12694.xml